ArticleNeurology(R) neuroimmunology & neuroinflammation2021
Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review.Journal of neurology · 2024Pooled it
- COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis.Multiple sclerosis and related disorders · 2022Pooled it
- Optimizing the Use of Anti-CD20 Agents in Multiple Sclerosis and Other Autoimmune Central Nervous System Disorders: A Narrative Review.Neurology and therapy · 2026Review
- Review
- Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan.Neurology and therapy · 2026Article
- Article
- Neuromyelitis optica spectrum disorder overlapping with Sjögren's disease: immunopathological links and therapeutic implications.Frontiers in immunology · 2026Review
- CAR T cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders.Journal of neuroinflammation · 2025Review
- Double-seronegative neuromyelitis optica: it is possible to interrupt treatment after 10 years of stability.Arquivos de neuro-psiquiatria · 2025Review
- Frequency of Seroconversion in Aquaporin-4 Antibody Testing: Insights From Real-World Data.Annals of clinical and translational neurology · 2025Article
- Adherence matters: catastrophic NMOSD relapse after missed eculizumab infusions.Journal of neurology · 2025Article
- Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study.Journal of neurology · 2025Article
- Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies.Annals of clinical and translational neurology · 2025Article
- A Case Report of Neuromyelitis Optica Spectrum Disorder in a Young Patient With Systemic Lupus Erythematosus.Cureus · 2025Article
- Is a Benign Disease Course Possible in Untreated AQP4-IgG NMOSD?European journal of neurology · 2025Article
- Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.Neurology and therapy · 2024Review
- Treatment of neuromyelitis optica spectrum disorder: revisiting the complement system and other aspects of pathogenesis.Wiener medizinische Wochenschrift (1946) · 2024Review
- Soluble biomarkers for Neuromyelitis Optica Spectrum Disorders: a mini review.Frontiers in neurology · 2024Review
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.Journal of neurology · 2024Review
- Comparison of inebilizumab or rituximab in addition to glucocorticoid therapy for neuromyelitis optica spectrum disorders.International journal of ophthalmology · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the outcomes of immunosuppressive therapy (IST) discontinuation in patients with neuromyelitis optica spectrum disorder (NMOSD) after a sustained remission period.
methodsWe retrospectively reviewed the medical records of 17 patients with antiaquaporin-4 antibody-positive NMOSD who discontinued IST after a relapse-free period of ≥3 years.
resultsIST was discontinued at a median age of 40 years (interquartile range [IQR], 32-51) after a median relapse-free period of 62 months (IQR, 52-73). Among the 17 enrolled patients, 14 (82%) relapsed at a median interval of 6 months (IQR, 4-34) after IST discontinuation, 3 (18%) of whom experienced severe attacks; notably, all 3 of these patients had a history of severe attack before IST. These 3 patients received steroids, followed by plasma exchange for acute treatment, but 2 exhibited poor recovery and significant disability worsening at 6 months after relapse.
conclusionsIST discontinuation may increase the risk of relapse in seropositive patients with NMOSD even after 5 years of remission. Given the potentially devastating consequence of a single attack of NMOSD, caution is advised with IST discontinuation, particularly in patients with severe attack before IST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.